Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Mitarbeiter des Rudolf-Boehm-Institutes
Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma
Untersuchung der biologischen Aktivität von Nanopartikeln in Tumor- schnittkulturen
Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma
PDF) The proto-oncogene Pim-1 is a target of miR-33a | Marshall Thomas - Academia.edu
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Biocompatibility and Efficacy of Oligomaltose-Grafted Poly(ethylene imine)s (OM-PEIs) for in Vivo Gene Delivery
Loop | Achim Aigner
Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Kn
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Mitarbeiter des Rudolf-Boehm-Institutes
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Con
Multiple effects of the special ATâ•'rich binding protein 1 (SATB1) in colon carcinoma
Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo
Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model
Analysis of SATB1 in Head and Neck Squamous Cell Carcinoma
MedTech-2022 Conferences | MedTech -2022 | MedTech 2022 Events | Pharma Industry and MedTech | MedTech Conferences | MedTech Meetings | Pharma Industry and MedTech | | Pharma Industry and MedTech Congress
Leipziger Pharmakologen forschen an Molekülen gegen Prostatakrebs
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
